(Q34089567)

English

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

based on heuristic

inferred from title

Robert Peter Gale

9

object named as

Robert Peter Gale

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Hillard M. Lazarus

1

object named as

Hillard M Lazarus

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

24

object named as

Julie M Vose

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

20

object named as

Harry C Schouten

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Koen van Besien

23

object named as

Koen van Besien

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Philip L McCarthy

16

object named as

Philip L McCarthy

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

11

object named as

Gregory A Hale

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

David J. Inwards-Breland

12

object named as

David J Inwards

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Brian J Bolwell

7

object named as

Brian J Bolwell

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

21

object named as

Shimon Slavin

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Parameswaran Hari

25

object named as

Parameswaran N Hari

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jeanette Carreras

3

object named as

Jeanette Carreras

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Richard Maziarz

15

object named as

Richard T Maziarz

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Brandon M Hayes-Lattin

4

object named as

Brandon M Hayes-Lattin

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

8

object named as

César O Freytes

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Carleen Klumpp-Thomas

13

object named as

Thomas R Klumpp

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

6

object named as

Jacob D Bitran

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J Douglas Rizzo

18

object named as

J Douglas Rizzo

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Mei-Jie Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Asli Selmin Ataergin

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Steven C Goldstein

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

David I Marks

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Santiago Pavlovsky

17

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Thomas C Shea

19

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jane N Winter

22

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

4 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Biology of Blood and Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

35-45

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

The whys and hows of hematopoietic progenitor and stem cell mobilization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Autologous and allogeneic transplantation for aggressive NHL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Outcome of relapsed non-Hodgkin's lymphoma patients after allogeneic and autologous transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

5 July 2018

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2929576

28 October 2018

Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma: updated results of the Utrecht experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/20053330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.BBMT.2009.08.011

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34089567&oldid=1858006837"